Switch of noninvasive ventilation (NIV) to continuous positive airway pressure (CPAP) in patients with obesity hypoventilation syndrome: a pilot study
Sarah Orfanos, Dany Jaffuel, Christophe Perrin, Nicolas Molinari, Pascal Chanez, Alain Palot

To cite this version:
Sarah Orfanos, Dany Jaffuel, Christophe Perrin, Nicolas Molinari, Pascal Chanez, et al.. Switch of noninvasive ventilation (NIV) to continuous positive airway pressure (CPAP) in patients with obesity hypoventilation syndrome: a pilot study. BMC Pulmonary Medicine, BioMed Central, 2017, 17 (1), pp.50. 10.1186/s12890-017-0391-9. hal-01777702

HAL Id: hal-01777702
https://hal.archives-ouvertes.fr/hal-01777702
Submitted on 12 Jun 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Switch of noninvasive ventilation (NIV) to continuous positive airway pressure (CPAP) in patients with obesity hypoventilation syndrome: a pilot study

Sarah Orfanos 1*, Dany Jaffuel 2, Christophe Perrin 3, Nicolas Molinari 4, Pascal Chanez 5 and Alain Palot 5

Abstract

Background: Obesity is a major worldwide public health issue. The main respiratory complication stemming from obesity is obesity hypoventilation syndrome (OHS). Most of the OHS patients diagnosed during an exacerbation are treated with non invasive ventilation (NIV). Up to date, no prospective study has demonstrated in real life conditions the feasibility of a systematic protocolled switch of NIV to continuous positive airway pressure (CPAP), once stability is achieved.

Methods: In this prospective study, we included stable patients with OHS, with moderate to severe concomitant obstructive sleep apnea (OSA) and without obstructive pulmonary disease, who had been undergoing NIV for more than 2 months. The following measurements were performed, first with NIV and then after the switch to CPAP: diurnal arterial blood gas measurements; nocturnal oximetry and capnometry; mean compliance and AH1; measures of quality of life and quality of sleep.

Results: 22/30 patients accepted to participate in the study and 15/22 patients completed the study. There were no significant differences for pooled data in diurnal alveolar blood gases, nocturnal capnometry (p = 0.534), nocturnal oximetry (p = 0.218), mean compliance (p = 0.766), mean AH1 (p = 0.334), quality of life or quality of sleep. Eighty percent of the patients treated in this study favored CPAP over NIV.

Conclusion: This pilot study showed in real life conditions the possibility of a systematic switch of NIV to CPAP, in most stable patients with OHS, with similar efficacy on diurnal and nocturnal alveolar gas exchange, quality of life and quality of sleep.

Trial registration: ISRCTN13981084. Registered: 27 February 2017 (retrospectively registered)

Keywords: Obesity hypoventilation syndrome, Non invasive ventilation, Continuous positive airway pressure, Bilevel positive airway pressure, Obstructive sleep apnea

Background

Obesity is a major worldwide public health issue [1]. The main respiratory complication stemming from obesity is obesity hypoventilation syndrome (OHS). OHS was defined, in 1999, by the American Academy of Sleep Medicine as the association of obesity (BMI ≥ 30 kg/m2); daytime hypercapnia (paCO2 > 45 mm Hg); and sleep disordered breathing, after excluding other causes of hypoventilation [2]. OHS is a frequent condition with the prevalence of OHS in patients with a BMI ≥ 35 kg/m2 being 31% [3]. OHS is an underdiagnosed and undertreated condition [3, 4], despite the fact that a treatment with positive airway pressure improves quality of life and decreases mortality in these patients [3, 5]. The application of a positive airway pressure through noninvasive ventilation (NIV) or continuous positive airway pressure (CPAP), decreases morbidity in patients presenting with OHS [4, 6, 7].

* Correspondence: sarah.orfanos@gmail.com
1Aix-Marseille University, Faculté de médecine, 27 Boulevard Jean Moulin, 13005 Marseille, France
Full list of author information is available at the end of the article
To date, the main unresolved question is to determine the respective position of NIV and CPAP when treating these patients. If some studies have attempted to determine different OHSs phenotypes to predict the outcome of CPAP therapy [8–10]; only two studies prospectively compared NIV and CPAP treatment in OHS [5, 11]. To date, the superiority of NIV over CPAP in the treatment of OHS has not been proven. However, 26 to 50% of patients suffering from OHS are diagnosed in an acute setting [7, 8, 11, 12], and most often treated with NIV which remains their usual ventilatory mode for the rest of their life.

Once stability has been reached, the question then arises as to whether NIV should be switched to CPAP. To our knowledge, no prospective trial has evaluated in real life conditions the feasibility of a protocol switching stable patients from NIV to CPAP.

The purpose of this study was to test the feasibility and effect of a standardized protocol, switching patients with OHS, from NIV to CPAP. We hypothesized that there will be no difference in efficacy after switching NIV to CPAP, on AHI, diurnal and nocturnal alveolar gas exchange (day-time arterial blood gas (ABG), nighttime transcutaneous oxygen saturation and transcutaneous measurement of pCO2 (ptCO2)), but also on sleepiness, quality of sleep and quality of life (Epworth Sleepiness Scale (EPS), Pittsburgh Sleep Quality Index (PSQI), Severe Respiratory Insufficiency questionnaire (SRI)).

**Methods**

**Patients**

Patients over 18 years old, suffering from OHS, defined as an association of obesity (BMI ≥ 30 kg/m2) and daytime hypercapnia (pCO2 > 45 mm Hg), who had been undergoing NIV for more than 2 months, were prospectively recruited from February 2015 to February 2016 in the pulmonology wards of the university hospital (hôpital Nord) and the military hospital (hôpital Laveran) in Marseille, France. To be included, patients had to be clinically stable for at least 4 weeks before enrollment in the study (no hospitalization or emergency admission). The exclusion criteria were: patients who presented hypercapnia secondary to other causes (obstructive pulmonary diseases (FEV1/FVC < 70), interstitial lung diseases, neuromuscular or chest wall diseases, severe hypothyroidism or congenital central hypoventilation syndrome), and patients unable to give informed consent.

This trial respected the ethical principles of the declaration of Helsinki and was approved by the local ethic committee of the Assistance Publique Hôpitaux de Marseille (AP-HM). Written informed consent was obtained from all patients. The use of data was approved by the Data Privacy Officer of the hospitals (AP-HM).

**Study protocol**

Patients who had been undergoing NIV for at least the last 2 months, were prospectively included in the study by the investigators, during a follow-up outpatient clinic.

During this clinic, the following clinical information were collected: history of the diagnosis of OHS, occurrence of acute exacerbations, NIV settings: brand, mode, respiratory rate (RR), expiratory positive airway pressure (EPAP), inspiratory positive airway pressure (IPAP) and interfaces.

The settings were in accordance with the American Academy of Sleep Medicine (AASM) recommendations [13]. NIV settings were optimized in order to avoid patient-ventilator dyssynchrony and to correct remaining respiratory events during sleep, according to the recommendations of the somnoNIV group [14].

Quality of life was evaluated using the SRI questionnaire; daytime sleepiness was evaluated using the ESS questionnaire; and quality of sleep was evaluated using the PSQI questionnaire.

Finally, an ABG analysis was performed, during the consultation, between 10 and 12 am in an awake, seated patient, at rest for at least 10 min.

During one night with NIV, at home, the patient underwent: (i) nocturnal oximetry using a pulse oximeter (Rescan® software, Resmed®, Australia, New South Wales, Bella-Vista), on which were calculated the percentage of recording time with SaO2 < 90% (RT < 90%) and the oxygen desaturation index (ODI) (defined as the number of time per hour the oxygen saturation drops by ≥ 4%); (ii) nocturnal transcutaneous capnometry using a transcutaneous capnometer (Tosca 500®, Radiometer®, Crawley, UK), on which was calculated the mean ptCO2; (iii) a report of the mean compliance, the median leak, the mean tidal volume and the mean AHI index of the last month spent with NIV was extracted (Rescan® software for Resmed®, Australia New South Wales, Bella-Vista NIV and Directview® for Philips-Respironics®, Murraysville, Pennsylvania, USA NIV).

After undergoing these procedures, the patients underwent NIV withdrawal for seven nights. At the end of this week, pulmonary function tests (PFT) were performed according to the American Thoracic Society and European Respiratory Society 2005 guidelines [15], and an overnight polygraphy during spontaneous breathing was performed (Alice PDx® Philips-Respironics®, Murraysville, Pennsylvania). Polysomnographic recordings were analyzed by a blinded pulmonologist certified in sleep medicine, respiratory events were scored manually according to the AASM 2012 manual [16]. The AHI, RT < 90% and ODI on this polygraphy during spontaneous breathing were reported. At this stage of the trial, patients exhibiting obstructive ventilatory disorder (FEV1/FVC < 70) or mild OSA (AHI < 15/h), were not switched to CPAP and continued their...
treatment with NIV. All the other patients were switched to CPAP, the settings were as follow: constant pressure, EPAP 2 cm H2O above the EPAP of the previous NIV to compensate for the absence of an IPAP on the CPAP, settings were not adjusted until measurements were repeated more than a month after this switch.

After more than a month with CPAP; SRI, ESS and PSQI questionnaires were reevaluated. An ABG analysis was performed in the same conditions as previously described. During one night with CPAP, at home, the patient underwent: (i) nocturnal oximetry; (ii) nocturnal transcutaneous capnometry; (iii) a report of the mean compliance, the median leak and the mean AHI index of the last month spent with CPAP was extracted. (Fig. 1).

As a secondary analysis, we analyzed the characteristics of patients failing NIV and CPAP using Salord et al. criteria to define failure: more than 30% of recording time spent below 90% saturation or paCO2 > 45 mm Hg, to determine if a characteristic could be used as a prognostic factor of ventilation failure [10].

**Statistical analysis**
Continuous data were expressed in means and SDs and categorical data were expressed as percentages and absolute.

Normality was assessed using Shapiro-Wilk normality test. Intra-group changes in variables measured at first with NIV and after the switch to CPAP were assessed using paired t-tests or non-parametric Wilcoxon tests depending on normality.

When comparing two independent groups (NIV failure, NIV success), unpaired t-tests or non-parametric Mann–Whitney tests depending on normality were used for continuous variables and χ² tests for categorical variables.

**Results**
**Study population**
Twenty-two patients were included. Five dropped-out due to unwillingness to be hospitalized for the polygraphy prior to the switch to CPAP. Two patients were excluded prior to the switch, one had an obstructive syndrome on the PFT, and the other had an AHI < 15/h on the polygraphy. Fifteen of the 30 patients who were initially selected, were switched to CPAP (Fig. 2).

Anthropometric characteristics of the patients are shown in Table 1.

Seven nights after the NIV was discontinued, polygraphy of the weaning period showed a high mean AHI (AHI = 53.5/h ±26.9) and the mean RT < 90% was 21.8% (24.2) (Table 2).

Regarding settings, all NIV were in spontaneous timed (ST) mode, mean EPAP was 7.7 ± 1.8 cm H2O, mean IPAP was 18.3 ± 3 cm H2O, mean back-up RR was 13.9 ± 1.8 cycles/min. Two patients received additional oxygen therapy, flow rates were not modified after switching to CPAP. (Table 3).

**Effect of the switch to CPAP on the measured data**
There were no significant differences, after the switch to CPAP, in mean AHI, diurnal and nocturnal alveolar gas exchanges (diurnal ABG, nocturnal oximetry and tran-cutaneous capnometry), median leaks and compliance (Table 4, Fig. 3).

Regarding ESS, SRI and PSQI scores, the only significant difference was in the ESS, which was lower after the switch to CPAP (8.21 ± 5.54 vs 4.29 ± 3.43) (p = 0.004). There were no significant differences in the SRI and all its subscales and in the PSQI and all its components between before and after the switch to CPAP. (Table 5, Fig. 4).

At the end of the trial, through a self-administered questionnaire, the patients’ preference for one mode of ventilation was determined. Twelve patients (80%)
reported that they preferred CPAP over NIV and wanted to continue their treatment with CPAP. Two patients (13%) had no preference. Only one patient wanted to discontinue CPAP and go back to NIV, despite the fact that there were no objective criteria of deterioration during CPAP treatment.

Safety
None of the patients presented with clinical deterioration after more than a month of CPAP and needed to be switched back to NIV. Two patients were admitted in the intensive care unit during the trial, due to causes unrelated to the mode of ventilation. One presented with acute renal failure complicated by symptomatic hyperkalemia and the other with left heart failure secondary to non-compliance to diuretics.

Cost
When taking into account French social security reimbursement rate, NIV cost was 63.16€ per week and CPAP cost was 18€ per week. This switch may allow an economy of 2348€ per year per patient.

NIV failure
When analyzing the characteristics of the patients failing NIV, according to Salord’s criteria: more than 30% of recording time spent below 90% saturation or paCO2 > 45 mm Hg; BMI was the only factor associated with NIV failure ($p = 0.014$) (Table 6).

Discussion
This prospective open trial, testing the feasibility of a protocol switching NIV to CPAP in stable patients in real life conditions, suggests the possibility of this switch in patients suffering from OHS with an AHI $\geq 15$/h and without pulmonary obstructive disease. In these conditions, we reported no significant treatment effect differences between before and after the switch to CPAP in diurnal and nocturnal alveolar gas exchange, mean AHI, mean compliance, quality of sleep and quality of life. In addition, 80% of patients preferred CPAP over NIV.

The pathophysiology of OHS is complex and multifactorial. Eventually leading to chronic, diurnal hypercapnia resulting from an imbalance between apnea and interapnea periods and deficiency of the compensatory mechanisms to unload the carbon dioxide in excess [17, 18]. This suggests the need to determine different phenotypes of OHS, and therefore adapt therapeutic intervention according to the phenotype. Therefore we have chosen in this trial, to exclude from the study, patients with an AHI $< 15$/h, speculating that CPAP mechanism to treat hypoventilation was mostly due to the correction of apneas and hypopneas. Indeed, if CPAP is not
intrinsic the most efficient treatment of hypoventilation, it is still effective on most of the pathophysiological mechanisms leading to OHS by decreasing upper airways resistance, increasing central response to hypercapnia and hypoxemia [19, 20], increasing lung volumes, treating atelectasis, decreasing intrinsic PEEP [21]. This is the reason why CPAP is efficient in most patients with OHS associated with OSA.

Two prospective randomized trials have compared the efficacy of CPAP and NIV in patients with OHS [5, 11]. These two prospective studies corroborate the fact that patients with OHS and concomitant OSA can be treated with CPAP. Piper and colleagues did not find a significant difference, at three months, in daytime paCO2 between the two groups NIV and CPAP [11]. However in this study, nine of the 45 patients initially selected were excluded from the trial, due to persisting nocturnal hypoxemia or nocturnal hypercapnia on the first night of CPAP titration. Treating hypoventilation in some phenotypes may take up to a few weeks [22], excluding patients after one night of CPAP titration is debatable.

Table 1 Baseline characteristics

| Baseline characteristics | n = 15 |
|--------------------------|--------|
| Sex (male)               | 5 (33.3%) |
| Age (years)              | 68.8 ± 11.2 |
| BMI (kg/m²)              | 41.7 ± 7.16 |
| Neck circumference (cm)  | 43.6 ± 4.5 |
| Waist/ Hip ratio         | 0.95 ± 0.08 |
| pH on ABG before initiating NIV | 7.38 ± 0.06 |
| PaCO2 on ABG before initiating NIV (mmHg) | 57.7 ± 7.6 |
| PaO2 on ABG before initiating NIV (mmHg) | 62.6 ± 18.8 |
| HCO3- before initiating NIV (mmol/L) | 31.8 ± 5.1 |
| Actual or past smokers   | 7 (46.7%) |
| Pack per year            | 38.1 ± 30.9 |
| Cardiovascular comorbidities | 13 (86.7%) |
| Hypertension             | 12 (80%) |
| Dyslipidemia             | 12 (80%) |
| Diabetes                 | 9 (60%) |
| Cardiac disease          | 12 (80%) |
| Ischemic cardiac disease | 5 (33.3%) |
| Cardiac arrhythmia       | 5 (33.3%) |
| LVEF (%)                 | 56 ± 14.3 |
| Diastolic dysfunction    | 8 (61.5%) |
| Diagnosis made during an exacerbation | 12 (80%) |

Data are expressed in n (%) and mean ± standard deviation

Definition of abbreviations: BMI body mass index, ABG arterial blood gas, NIV non invasive ventilation, LVEF left ventricular ejection fraction

Table 2 Wash out period: pulmonary function tests and polygraphy

| PFT and Polygraphy (during withdrawal) | n = 15 |
|----------------------------------------|--------|
| FEV1/FVC (%)                           | 79.5 ± 7.4 |
| FEV1 (%)                               | 69.2 ± 16.4 |
| FVC (%)                                | 70.2 ± 17.3 |
| AHl (n/h)                              | 53.5 ± 26.9 |
| RT < 90% (%)                           | 21.8 ± 24.2 |
| ODI ≥ 4% (n/h)                         | 42.1 ± 39.5 |

Data are expressed in mean ± standard deviation

Definition of abbreviations: PFT pulmonary function test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, AHl apnea hypopnea index, RT < 90% percentage of recording time below 90% saturation, ODI oxygen desaturation index

Table 3 NIV and CPAP settings

| NIV and CPAP settings | n = 15 |
|-----------------------|--------|
| NIV mode              | ST     |
| NIV EPAP (cm H2O)     | 7.7 ± 1.8 |
| NIV IPAP (cm H2O)     | 18.3 ± 3 |
| NIV RR (n/min)        | 13.9 ± 1.8 |
| NIV VT (ml)           | 508.3 ± 264 |
| CPAP EPAP (cm H2O)    | 98.1 ± 1.4 |
| Oronasal mask         | 10 (66.7%) |
| Nasal mask            | 3 (20%) |
| Nasal pillows          | 2 (13.3%) |

Data are expressed in mean ± standard deviation and n (%)

Definition of abbreviations: NIV non invasive ventilation, CPAP continuous positive airway pressure, EPAP expiratory positive airway pressure, IPAP inspiratory positive airway pressure, RR respiratory rate, VT tidal volume

Table 4 Measured data with NIV and one month after the switch to CPAP

| Measured data       | NIV | CPAP | P value |
|---------------------|-----|------|---------|
| Pa CO2 (mm Hg)      | 40.4 ± 5.1 | 40.9 ± 6.7 | 0.323 |
| Pa O2 (mm Hg)       | 73.3 ± 8.8 | 74.4 ± 8.8 | 0.235 |
| pH                  | 7.43 ± 0.04 | 7.43 ± 0.03 | 0.508 |
| HCO3 (mmol/L)       | 26.3 ± 3.14 | 26.6 ± 3.6 | 0.511 |
| RT < 90% (%)        | 28.1 ± 27.2 | 20.5 ± 25.2 | 0.218 |
| ODI ≥ 4% (n/h)      | 11.92 ± 17.31 | 10 ± 9.41 | 0.285 |
| Transcutaneous pCO2 (mm Hg) | 49.9 ± 10.12 | 48.4 ± 5.14 | 0.534 |
| AHl (n/h)           | 5.99 ± 10.96 | 5.49 ± 7.84 | 0.334 |
| Leaks (L/sec)       | 3.8 ± 10.09 | 2.9 ± 6.1 | 0.844 |
| Compliance (h)      | 6.73 ± 2.66 | 68 ± 2.27 | 0.766 |

Data are expressed in mean (standard deviation)

Definition of abbreviation: NIV non invasive ventilation, CPAP continuous positive airway pressure, RT < 90% percentage of recording time below 90% saturation, ODI oxygen desaturation index, AHl apnea hypopnea index
using CPAP more than 4 h per night. Moreover, the authors found a significant difference, favoring NIV, on the 6 min’ walk test and respiratory function tests.

The heterogeneity in responses to CPAP, led some studies to try to define phenotypes of OHS and predictor factors of CPAP failure. Therefore, patients exhibiting a higher BMI, a higher percentage of recording time below 90% saturation, a lower AHI, or a decreased forced vital capacity could be at higher risk of CPAP failure, even though these predictor factors are not constantly found in all studies [8–10]. In our study, we found that only BMI had a significant association with CPAP or NIV failure (Table 6). When using the two criteria defining failure in Salord and colleagues study [10] (more than 30% of recording time spent below 90% saturation or paCO2 > 45 mm Hg), in our study 8/15 patients would

---

**Fig. 3** Measurement of mean AHI; diurnal and nocturnal alveolar gas exchange parameters and mean compliance, in 15 patients, with NIV and one month after the switch to CPAP. Definition of abbreviations: NIV: Non Invasive Ventilation; CPAP: continuous positive airway pressure; AHI: Apnea Hypopnea Index; RT < 90% spO2: percentage of recording time below 90% saturation; NS: no significant difference p > 0.05
be categorized as NIV failure and 7/15 as CPAP failure. Interestingly, the seven patients failing CPAP were the same patients who were failing NIV before the switch. We do not think this failure can be attributed to NIV or CPAP settings in our study. Mean EPAP was 8 cm H2O, mean IPAP was 18 cm H2O, back-up RR was 14 cycles/min, all NIV were in ST mode. Concerning CPAP, mean EPAP was 9.8 cm H2O. These pressures are concordant with previous trials [5, 11].

Our study has some limitations. First of all it can be argued that the sample size in our study (15 patients) could be insufficient to detect a significant difference after the switch to CPAP, and that this absence of difference could be due to a lack of power. This study does not have the pretention to assert the absence of difference between NIV and CPAP at a larger scale, but describes a feasible protocol for most sleep clinic, to switch stable patients with OHS from NIV to CPAP. As suggested by our preliminary results, for some patients, the switch of NIV to CPAP can be deleterious emphasizing the need for a careful monitoring. A second limitation is that the results of our study can only be extended to patients with OHS and concomitant OSA with AHI ≥ 15/h, without obstructive pulmonary diseases, and cannot be used when treating patients in an acute state or with mild OSA. These drastic selection criteria aimed at targeting CPAP responders’ phenotypes and the limited number of patients included in the study could partly explain the stable diurnal capnia after the switch to CPAP in all of our patients. The

### Table 5 ESS, PSQI and its components, SRI and its subscales scores with NIV and one month after the switch to CPAP

| Scores     | NIV         | CPAP        | P value |
|------------|-------------|-------------|---------|
| ESS        | 8.21 ± 5.54 | 4.29 ± 3.43 | 0.004*  |
| PSQI       | 6.86 ± 4.77 | 6.14 ± 3.65 | 0.311   |
| Component 1| 1.07 ± 0.92 | 0.86 ± 0.53 | 0.500   |
| Component 2| 0.79 ± 1.37 | 1.29 ± 1.27 | 0.250   |
| Component 3| 0.93 ± 0.83 | 0.93 ± 1.07 | 1       |
| Component 4| 0.5 ± 0.85  | 0.57 ± 0.85 | 0.531   |
| Component 5| 1.29 ± 0.61 | 1.21 ± 0.43 | 1       |
| Component 6| 1.21 ± 1.48 | 0.43 ± 1.09 | 0.125   |
| Component 7| 1 ± 1.18    | 0.86 ± 1.03 | 0.766   |
| SRI        | 62.4 ± 19.46| 66.5 ± 17.32| 0.153   |
| SRI RC     | 70 ± 21.61  | 71.87 ± 21.58| 0.529   |
| SRI PF     | 48.61 ± 28.33| 46.13 ± 29.17| 0.404   |
| SRI AS     | 54.83 ± 28.80| 64.54 ± 22.04| 0.135   |
| SRI SF     | 70.83 ± 21.30| 75 ± 19.81   | 0.682   |
| SRI ANX    | 69.67 ± 16.74| 70.14 ± 18.02| 0.968   |
| SRI WB     | 61.31 ± 28.63| 73.21 ± 21.89| 0.240   |
| SRI SR     | 61.54 ± 23.52| 64.38 ± 22.25| 0.675   |

Data are expressed in mean (standard deviation)

Definition of abbreviations: NIV non invasive ventilation, CPAP continuous positive airway pressure, ESS epworth sleepiness scale, PSQI Pittsburgh sleep quality index, SRI severe respiratory insufficiency questionnaire, RC respiratory complaints, PF physical functioning, AS attendant symptoms, SF social functioning, ANX anxieties, WB well being, SR social relationships

*means significance with p value < 0.05

---

**Fig. 4** Changes in ESS, PSQI and SRI scores one month after the switch to CPAP. Definition of abbreviations: NIV: Non Invasive Ventilation; CPAP: Continuous Positive Airway Pressure; ESS: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep Quality Index; SRI: Severe Respiratory Insufficiency questionnaire; NS: no significant difference; *: significant difference p < 0.05
treatment of patients with OHS with pure hypoventilation and without OSA, is seldom discussed in scientific literature, and these patients still benefit from NIV in most teams [23]. For ethical reasons, we decided not to switch to CPAP, patients with mild OSA (AHI < 15/h), to not deprive these patients with previous acute exacerbation from an effective therapy.

To eliminate NIV persistent effect, we introduced in the protocol, a withdrawal from NIV for seven nights before starting CPAP, and reevaluated patients more than a month after starting CPAP. It is possible that not all persistent effects attributable to NIV were eliminated by this withdrawal [24]. An ideal protocol would have been to randomize patients into three groups: one group pursuing NIV, one group switching to CPAP and one group stopping ventilation; but this protocol did not seem ethical for patients withdrawn from ventilation, considering that a higher mortality rate has been reported in untreated patients with OHS [4, 6, 7]. In our study, 12 out of 15 patients were diagnosed with OHS and started on NIV, following an episode of exacerbation. This raises the question as to whether the diagnosis of OHS was made in excess in patients with normocapnic OSA undergoing an exacerbation. This assertion is however contradicted by the fact that nine out of the 12 patients diagnosed with OHS following an exacerbation, had high bicarbonates level (HCO3- > 28 mmol/l), in favor of chronic hypercapnia [25]. When measuring the AHI, we used the built-in software available in the NIV and the CPAP. Although the accuracy of these systems is debatable, recent studies are in favor of a good reliability of these built-in softwares [26].

**Conclusion**

In conclusion, this preliminary study showed in real life conditions, the possibility of a systemic switch of NIV to CPAP in most stable patients with OHS and a concomitant OSA, with similar efficacy on diurnal and nocturnal alveolar gas exchange, quality of life and quality of sleep. These results need to be confirmed by a larger trial that could also evaluate the clinical consequences of this switch in the longer term, especially cardio-vascular consequences.

**Abbreviations**

AASM: American Academy of Sleep Medicine; ABG: Arterial blood gas; AHI: Apnea hypopnea index; BMI: Body mass index; CPAP: Continuous positive airway pressure; EPAP: Expiratory positive airway pressure; EPS: Epworth sleepiness scale; FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity; HCO3-: Bicarbonates; IPAP: Inspiratory positive airway pressure; NIV: Noninvasive ventilation; ODI: Oxygen desaturation index; OHS: Obesity hypoventilation syndrome; OSA: Obstructive sleep apnea; PaCO2: Partial pressure of arterial carbon dioxide; PaO2: Partial pressure of arterial oxygen; PFT: Pulmonary function tests; PSQI: Pittsburgh sleep quality index; PtCO2: Transcutaneous measurement of carbon dioxide; RR: Respiratory rate; RT < 90%: percentage of recording time below 90% saturation

| Clinical characteristics | NIV failure (n = 8) | NIV success (n = 7) | P values |
|--------------------------|---------------------|---------------------|----------|
| Age (years)              | 67.12 ± 8.64        | 70.71 ± 14.04       | 0.555    |
| BMI (kg/m²)              | 46.54 ± 4.84        | 36.2 ± 5.07         | 0.014*   |
| Neck circumference (cm)  | 45.12 ± 5.64        | 41.93 ± 1.97        | 0.179    |
| Waist/Hip ratio          | 0.94 ± 0.08         | 0.97 ± 0.09         | 0.448    |
| PaCO2 at diagnosis (mm Hg) | 57.12 ± 8.56     | 58.29 ± 6.97        | 0.780    |
| Cardiovascular comorbidities | 7 (87.5%) | 6 (85.7%) | 1        |
| FVC (%)                  | 68.07 ± 19.46       | 70.49 ± 13.48       | 0.788    |
| AHI (n/h)                | 63.09 ± 28.53       | 42.54 ± 21.76       | 0.145    |
| RT < 90% (%)             | 26.45 ± 28.55       | 16.54 ± 18.89       | 0.450    |
| Diagnosis during an exacerbation | 6 (75%) | 6 (85.7%) | 0.605    |

Data are expressed in n (%); mean (standard deviation)

Definition of abbreviations: NIV non invasive ventilation, BMI body mass index, FVC forced vital capacity, AHI apnea hypopnea index, RT < 90% % of recording time below 90% saturation
Ethics approval and consent to participate
This trial respected the ethical principles of the declaration of Helsinki and was approved by the local ethic committee of the Assistance Publique Hôpitaux de Marseille (AP-HM). Written informed consent was obtained from all patients. The use of data was approved by the Data Privacy Officer of the hospitals (AP-HM).

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Aix-Marseille University, Faculté de médecine, 27 Boulevard Jean Moulin, 13005 Marseille, France. 2Département de Pneumologie, Hôpital Arnaud de Villeneuve, CHRU de Montpellier, 371 Avenue du Doyen Giraud, 34295 Montpellier, Cedex 5, France. 3Service de Pneumologie, Pôle des Spécialités Médicales, Centre Hospitalier de Cannes, 15 avenue des Broussailles, 06401 Cannes, France. 4INSERM U1046, Université de Montpellier 1 et Département Médical d’Information, Centre Hospitalier Universitaire, 34000 Montpellier, France. 5Clinique des Bronches, Allergies et du Sommeil, Assistance Publique Hôpitaux de Marseille, France et INSERM U1067, CNRS UMR 7333 Aix Marseille Université, 13015 Marseille, France.

Received: 23 September 2016 Accepted: 4 March 2017
Published online: 14 March 2017

References
1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.
2. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22(5):667–89.
3. Novbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, Gaudio JC, et al. Obesity-Associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116(1):1–7.
4. Pépin J-L, Borel J-C, Janssens J-P. Obesity hypoventilation syndrome: an underdiagnosed and undertreated condition. Am J Respir Crit Care Med. 2012;186(2):265–7.
5. Masa JF, Corral J, Alonso ML, Ordax E, Troncoso MF, Gonzalez M, et al. Efficacy of different treatment alternatives for obesity hypoventilation syndrome. Pickwick Study. Am J Respir Crit Care Med. 2015;192(1):86–95.
6. Budweiser S, Reidi SG, Jörres RA, Heinemann F, Pleifer M. Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. J Intern Med. 2007;261(4):375–83.
7. Piou P, Hamel JF, Person C, Meslier N, Racineux JL, Urban T, et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest. 2010;138(1):84–90.
8. Pérez de Llano LA, Golpe R, Ortiz Piquer M, Veres Ramacome A, Vázquez Caruncho M, López MJ, et al. Clinical heterogeneity among patients with Obesity Hypoventilation Syndrome: therapeutic implications. Respir. 2008;75(1):34–9.
9. Banerjee D, Yee BJ, Piper AJ, Zwillich CW, Grunstein RR. Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure. Chest. 2007;131(6):1678–84.
10. Sälorö N, Mayos M, Miralda RM, Farré A, Carreras M, Sust R, et al. Continuous positive airway pressure in clinically stable patients with mild-to-moderate obesity hypoventilation syndrome and obstructive sleep apnoea. Respir. 2013;18(7):1135–42.
11. Piper AJ, Wang D, Yee BJ, Barnes DJ, Grunstein RR. Randomised trial of CPAP vs bilevel support in the treatment of obesity hypoventilation syndrome without severe nocturnal desaturation. Thorax. 2008;63(5):395–401.
12. Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, Golpe R, Méndez Maroto L, Castro-Castro J, et al. Obesity-Hypoventilation Syndrome: Increased Risk of Death over Sleep Apnea Syndrome. PLoS ONE. 2015;10(2)e0117808.
13. NPPV Titration Task Force of the American Academy of Sleep Medicine. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2010;6(5):591–599.
14. Janssens J-P, Borel J-C, Pépin J-L, SommnoNIV Group. Nocturnal monitoring of home non-invasive ventilation: the contribution of simple tools such as pulse oximetry, capnography, built-in ventilator software and autonomic markers of sleep fragmentation. Thorax. 2011;66(5):438–45.
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry, Eur Respir J. 2005;26(2):319–38.
16. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the American Academy of Sleep Medicine. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2012;8(5):597–619.
17. Ayappa I, Berge KI, Norman RG, Oppenheimer BW, Rapoport DM, Goldring RM. Hypacopia and ventilatory periodicity in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2002;166(1):1125–5.
18. Norman RG, Goldring RM, Clain JM, Oppenheimer BW, Chaney AN, Rapoport DM, et al. Transition from acute to chronic hypacopia in patients with periodic breathing: predictions from a computer model. J Appl Physiol. 2006;100(5):1733–41.
19. Lin C. Effect of nasal CPAP on ventilatory drive in normocapnic and hypercapnic patients with obstructive sleep apnoea syndrome. Eur Respir J. 1994;11(1):2005–10.
20. Han F, Chen E, Wei H, He Q, Ding D, Strohl KP. Treatment effects on carbon dioxide retention in patients with obstructive sleep apnea-hypopnea syndrome. Chest. 2001;119(6):1814–41.
21. Steier J, Jolley CJ, Seymour J, Roughton M, Polkey MJ, Moxham J. Neural respiratory drive in obesity. Thorax. 2009;64(8):719–25.
22. Schönhofer B, Köhler D. Effect of non-invasive mechanical ventilation on sleep and nocturnal ventilation in patients with chronic respiratory failure. Thorax. 2000;55(4):308–13.
23. Ojeda Castillo E, De Lucas Ramos P, López Martin S, Resano Barrios P, Rodríguez Rodríguez P, Morín Cadco L, et al. Noninvasive mechanical ventilation in patients with obesity hypoventilation syndrome. Long-term outcome and prognostic factors. Arch Bronconeumol. 2015;51(2):61–8.
24. De Miguel Díez J, De Lucas Ramos P, Pérez Parra JI, Buendía García MJ, Cubillo Marcos JM, González-Moro JMR. Analysis of withdrawal from noninvasive mechanical ventilation in patients with obesity-hypoventilation syndrome. Medium term results. Arch Bronconeumol. 2003;39(7):292–7.
25. Mokhlesi B, Tubairat A, Falbuskowsitsch I, Wang Y, Evans A. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath. 2007;11(2):117–24.
26. Georges M, Adler D, Contal O, Espa F, Perig S, Pépin JL, et al. Reliability of apnea hypopnea index measured by a home B-level Pressure support ventilator versus a polysomnographic assessment. Respir Care. 2015;60(7):1051–6.